Carmine De Angelis
Carmine De Angelis/LinkedIn

Carmine De Angelis: Systemic Therapies After Progression on CDK4/6 Inhibitors in HR+/HER2− mBC

Carmine De Angelis, Associate Professor at Southern Higher School, Naples, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:

“Proud to share our latest work published in EClinicalMedicine

We conducted a comprehensive network meta-analysis of 28 randomized trials (n=6544) evaluating systemic therapies after progression on CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer.

We found that combinations of targeted agents with endocrine therapy or novel endocrine agents demonstrated favorable efficacy and safety profiles, especially in specific biomarker subgroups.

Antibody–drug conjugates also demonstrate strong efficacy in chemotherapy-resistant cases.

This work supports personalized treatment sequencing to improve patient outcomes.”

Title: Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysis

Authors: Roberto Buonaiuto, Mario Fordellone, Aldo Caltavituro, Maria Letizia Cataldo, Carmen Criscitiello, Maria Vittoria Dieci, Matteo Lambertini, Andrea Botticelli, Mario Giuliano, Antonio Giordano, Federica Mangiacotti, Angela Grieco, Alessandra Longobardi, Roberta Caputo, Martina Pagliuca, Claudio Vernieri, Luca Malorni, Lorenzo Gerratana, Grazia Arpino, Paolo Chiodini, Michelino De Laurentiis, Carmine De Angelis

Read the Full Article on EClinicalMedicine

Carmine De Angelis: Systemic Therapies After Progression on CDK4/6 Inhibitors in HR+/HER2− mBC

More posts featuring Breast Cancer.